I don't really care one way or t'other.....if BETonMACE hits on all three endpoints, then Bob is my uncle, heck Bob is every long's uncle in that case.  Obviously the less dlution the better, but if we hit on all 3 endpoints then I'll still be happy whether its 250 million shares out or even 400 million.

I was thinking that a pre-topline valuation of $1 or even $2 billion USD would not have been out of line...and while I guess its still possible its probably unlikely at this point.  Post top-line, if we hit the Biotech Trifecta.....then I'm thinking $5 billion USD minimum.  Amarin had almost 300 million issued and outstanding when Reduce-It hit 25% RRR on 5 point mace....and their PPS soared north of $20 USD.  If we can hit 25% or better on 3 point MACE, then that to me is the benchmark....$20 USD is about $27 CAD.  

Off to the tennis courts....can't wait to have this share offering stuff in the rear view mirror so the market can start focusing in on the upcoming results once again.